Pacer Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.09M | Sell |
288,231
-115,397
| -29% | -$3.64M | 0.02% | 505 |
|
|
2025
Q1 | $13.2M | Sell |
403,628
-1,193,828
| -75% | -$39.1M | 0.03% | 396 |
|
|
2024
Q4 | $57.8M | Sell |
1,597,456
-155,426
| -9% | -$5.62M | 0.12% | 179 |
|
|
2024
Q3 | $54.7M | Buy |
1,752,882
+403,028
| +30% | +$12.6M | 0.12% | 196 |
|
|
2024
Q2 | $36.1M | Buy |
1,349,854
+1,348,508
| +100,186% | +$36.1M | 0.08% | 235 |
|
|
2024
Q1 | $45.9K | Buy |
1,346
+716
| +114% | +$24.4K | ﹤0.01% | 3201 |
|
|
2023
Q4 | $18.2K | Buy |
630
+327
| +108% | +$9.46K | ﹤0.01% | 3329 |
|
|
2023
Q3 | $8.35K | Sell |
303
-448,692
| -100% | -$12.4M | ﹤0.01% | 2574 |
|
|
2023
Q2 | $13.5M | Buy |
+448,995
| New | +$13.5M | 0.05% | 304 |
|
|
2023
Q1 | – | Sell |
-277,169
| Closed | -$9.89M | – | 2366 |
|
|
2022
Q4 | $9.89M | Buy |
+277,169
| New | +$9.89M | 0.05% | 341 |
|
|
2021
Q4 | – | Sell |
-90,866
| Closed | -$2.42M | – | 2225 |
|
|
2021
Q3 | $2.42M | Sell |
90,866
-5,168
| -5% | -$138K | 0.03% | 626 |
|
|
2021
Q2 | $2.96M | Buy |
96,034
+40,518
| +73% | +$1.25M | 0.04% | 503 |
|
|
2021
Q1 | $1.45M | Buy |
55,516
+37,016
| +200% | +$969K | 0.03% | 622 |
|
|
2020
Q4 | $465K | Buy |
18,500
+3,077
| +20% | +$77.3K | 0.01% | 999 |
|
|
2020
Q3 | $321K | Buy |
15,423
+7,406
| +92% | +$154K | 0.01% | 1112 |
|
|
2020
Q2 | $190K | Sell |
8,017
-2,083
| -21% | -$49.4K | ﹤0.01% | 810 |
|
|
2020
Q1 | $201K | Sell |
10,100
-10,751
| -52% | -$214K | ﹤0.01% | 414 |
|
|
2019
Q4 | $495K | Sell |
20,851
-2,452
| -11% | -$58.2K | 0.02% | 784 |
|
|
2019
Q3 | $640K | Buy |
23,303
+7,005
| +43% | +$192K | 0.01% | 944 |
|
|
2019
Q2 | $539K | Buy |
16,298
+2,240
| +16% | +$74.1K | 0.01% | 955 |
|
|
2019
Q1 | $493K | Buy |
14,058
+2,098
| +18% | +$73.6K | 0.01% | 578 |
|
|
2018
Q4 | $397K | Buy |
+11,960
| New | +$397K | 0.01% | 162 |
|